Our Team

OcuCure Therapeutics has a seasoned management team with extensive domain experience. The team also has experience in creating and growing healthcare ventures.

Sunder H. Malkani
President and CEO

Sunder has many years of experience in creating and growing new businesses, primarily in the eye care space. He has been a senior executive of major multinational companies and in start-up ventures. Sunder developed and commercialized the AOSEPT contact lens solution, later acquired by CIBA Vision, a Novartis company. He was a member of the Innotech executive team, a venture funded start-up company that went public on the NASDAQ and was subsequently acquired by Johnson & Johnson. Most recently, Sunder was the EVP for Business Development at The Egg Factory, a start-up technology development company and a developer and supplier/vendor of proprietary innovations to large global companies.

Sunder has a B.S. in Mechanical Engineering from the Indian Institute of Technology (IIT), New Delhi, India, an M.S. in Industrial Engineering from the University of New York at Buffalo.

Patricia B. Williams, Ph.D.
Consultant and Chief Scientific Officer

Patricia WilliamsPat has many years of experience in both preclinical and clinical pharmacology. She focuses on safe and efficacious treatments for blinding eye diseases. Pat is a founding member of EyeRx Research Inc where she has teamed with ophthalmologists and other scientists and developed several ophthalmic drugs through to clinical trials and the FDA regulatory process. Pat's team has been awarded seven patents.

Pat is author of over 50 publications and a frequent guest speaker at national and international conferences. She serves as a consultant to the FDA, NASA, the pharmaceutical industry and the NIH to evaluate proposals for NIH funding. Pat graduated from the University of Michigan with a B.S. in pharmacy and with a Ph.D. in pharmacology from the Medical College of Virginia, Virginia Commonwealth University.

Craig Greven, M.D.
Consultant and Chief Medical Officer

Craig Greven, M.D.Dr. Greven is the Chairman of the Department of Ophthalmology at Wake Forest University Eye Center .  Dr. Greven is a renowned retinal specialist and has been involved in several clinical trials for AMD and other retinal pharmaceuticals. He received his medical degree from Bowman Gray School of Medicine and completed his retinal fellowship at Wills Eye Hospital.

Sam English, Ph.D.
Consultant and VP Pharmaceutical Services

Sam is the Director of Research for Carilion Health System. He has extensive experience with biomedical startup companies and is extremely knowledgeable about university tech transfer processes and in-licensing from academic institutions.

Sam has licensed 10 technologies from university partners. Sam has a B.S. in Microbiology and a Ph.D. in Biochemistry from Clemson University. He is a member of the Licensing Executives Society and the Association of University Technology Managers.

Board of Directors

W. Ben Deibler: Ben is a veteran of the eye care business. Prior to retiring, he was the Global VP of Business Development for Johnson & Johnson Vision Care Inc. Before that, Ben was the President & CEO of Vaso Products, Inc and VP of Johnson & Johnson Development Corp (J&J's venture arm). Ben has held numerous other executive positions within the J&J organization. He has a B.S. in Finance from Drexel University and an MBA from Farleigh Dickinson University.

Richard M. Haugen: Rick has a good understanding of the pharmaceutical business, especially ophthalmics. He was the Chief Operating Officer and on the Board of Directors at Allergan a dominant company in the global ophthalmic pharmaceuticals business. Currently, Rick is the President of Newport Assets, Inc., an investment management company in California. Prior to this he was the President and CEO for Amylin Pharmaceuticals in San Diego, CA.  Rick has a MBA in Finance from the University of Southern California.

Steve M. Martin: Steve founded CIBA Vision and CIBA Vision Ophthalmics (now Novartis Ophthalmics). Prior to retiring as President of CIBA Vision Ophthalmics, Steve also advised Novartis on new life science ventures. Currently he is the CEO of HiTech Partners, a company advising early stage high technology companies. Steve has served as a Director on Boards of many private and public companies. Currently, he sits on the Board of La Jolla Pharmaceuticals, a NASDAQ company, and Alimera Sciences, a venture funded start-up company. Steve is a graduate of Wake Forest University and attended the Woodrow Wilson College of Law.

Paul S. Williams: Paul is co-founder and President/CFO of Heflin & Williams, Inc., a marine engineering and management consulting service company.  Paul is also a Board Member of EyeRx Research, Inc., an ophthalmic drug development company. Paul was the Director of Contracts for Newport News Shipbuilding, the largest US shipbuilder and a major defense contractor for nuclear powered aircraft carriers and submarines. Paul has an engineering degree from University of Michigan and an MBA from the College of William & Mary.


Privacy Policy � copyright � 2006 � All Rights Reserved � Sit e Credits